NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 182)
Posted On: 07/20/2018 4:10:23 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Continues to Demonstrate its Value
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) believes that in the future, up to 80 percent of its total revenue could stem from licensing deals for its patented DehydraTECH™ delivery technology. An article discussing the company reads: “The company’s patented DehydraTECH™ is key to LXRP’s valuation. The technology is being tested in human clinical studies for the delivery of cannabinoids through ingestible means. Results thus far have shown increased absorption rates with reduced time to enter the bloodstream and reported improvements in the taste and smell of edible products. … Lab tests on mice have shown a 50 percent improvement in active ingredients, such as nicotine, being absorbed into the bloodstream. They demonstrated even higher percentage levels absorbed into the brain. Bunka said that these results could potentially have an important impact on future treatment of cancer and brain tumors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) believes that in the future, up to 80 percent of its total revenue could stem from licensing deals for its patented DehydraTECH™ delivery technology. An article discussing the company reads: “The company’s patented DehydraTECH™ is key to LXRP’s valuation. The technology is being tested in human clinical studies for the delivery of cannabinoids through ingestible means. Results thus far have shown increased absorption rates with reduced time to enter the bloodstream and reported improvements in the taste and smell of edible products. … Lab tests on mice have shown a 50 percent improvement in active ingredients, such as nicotine, being absorbed into the bloodstream. They demonstrated even higher percentage levels absorbed into the brain. Bunka said that these results could potentially have an important impact on future treatment of cancer and brain tumors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼